Cytotoxicity Of Orthodontic Temporary Anchorage Devices In Vitro

Manika Patwari
Marquette University

Recommended Citation
http://epublications.marquette.edu/theses_open/197
CYTOTOXICITY OF ORTHODONTIC TEMPORARY ANCHORAGE DEVICES ON HUMAN PERIODONTAL LIGAMENT FIBROBLASTS

IN VITRO

by

Manika Patwari, D.M.D.

A Thesis submitted to the Faculty of the Graduate School,
Marquette University,
in Partial Fulfillment of the Requirements for
the Degree of Master of Science

Milwaukee, Wisconsin
May 2013
ABSTRACT

CYTOTOXICITY OF ORTHODONTIC TEMPORARY ANCHORAGE DEVICES ON HUMAN PERIODONTAL LIGAMENT FIBROBLASTS

IN VITRO

Manika Patwari, D.M.D

Marquette University, 2013

Introduction: Cytotoxicity is a major concern in the clinical application of dental materials including Temporary Anchorage Devices (TADs). The purpose of this study was to test the cytotoxicity of four of the commercially available brands of TADs (Aarhus, American Orthodontics; Dual top, RMO; Vector TAS, ORMCO; Unitek TAD, 3M UNITEK).

Materials and Methods: Twenty-four (six from each brand) TADs were individually incubated in complete cell culture medium and shaken at a rate of 1.5 rpm at 37°C for 30 days to generate the conditioned medium (CM). To test the cytotoxicity, human periodontal ligament fibroblasts (hPDLF) were exposed to the CM for 24 hours. As endpoints, morphological changes were observed along with cell death and damage which were quantified by MTT and LDH assays, followed by statistical analysis of one-way ANOVA with Bonferroni adjustment.

Results: No morphological changes were found in any of the four types of TADs compared to the control cells. LDH assay showed that none of the tested TADs caused significant cell death after CM treatment in contrast to the positive control ($P > 0.05$). No significant intragroup differences were found between any of the four brands of TADs ($P > 0.05$). MTT assay showed similar results as for the LDH assay, except for a marginally significant increase of MTT release found in the TADs from 3M UNITEK compared to the negative control ($P = 0.047$).

Conclusions: According to the ISO10993:5 standards, none of the tested TADs exhibited statistically significant cytotoxicity, suggesting their safe clinical application.
ACKNOWLEDGEMENTS

Manika Patwari, D.M.D

My sincere appreciation and thanks to Dr. Dawei Liu for his vital role in the inception, study design, methodology and statistics of this project. His utmost help, support and guidance throughout every step of this project and during my education at Marquette University has been phenomenal. This project would not have been realized without the time and sincere efforts of Dr. Zhibin Chen. She made the tedious laboratory procedure of the project simple and straightforward.

I truly appreciate Dr. Jeffery Toth, Dr. Jose Bosio and Dr. Arthur Hefti for being a part of my thesis committee and for their constructive feedback, support and guidance.

I would also like to extend my thanks to American Orthodontics, Rocky Mountain Orthodontics, 3M Unitek and Ormco for their generous donations of miniscrew implants. A warm thanks to Mr. James Brozek for helping us with the photographs and Dr. Lobner for his help in troubleshooting with the experimental set up for our project.

I am especially grateful to my husband Apoorv, our parents and my sister for their unconditional love and support. I feel truly blessed to have such a wonderful family.
# TABLE OF CONTENTS

ACKNOWLEDGEMENTS...........................................................................................................i

LIST OF TABLES......................................................................................................................iv

LIST OF FIGURES....................................................................................................................v

CHAPTERS

1. **INTRODUCTION**.............................................................................................................. 1

2. **REVIEW OF LITERATURE**........................................................................................... 2
   - Anchorage: The backbone of orthodontics................................................................. 2
   - Need for skeletal anchorage: historical development............................................... 2
   - Classification of temporary anchorage devices.......................................................... 3
   - Types of applications as anchorage........................................................................... 6
   - Indications and contraindications.............................................................................. 6
   - Composition of TADs.................................................................................................... 7
   - Components of TADs.................................................................................................... 8
   - Biocompatibility............................................................................................................ 9
     - Host – miniscrew interactions............................................................................. 11
     - Biocorrosion............................................................................................................ 11
     - Stability ................................................................................................................. 14
   - Measuring biological response- *in vitro* testing...................................................... 17
   - Principles of *in vitro* cytotoxicity testing................................................................. 18
     - *In vitro* cytotoxicity test procedures................................................................. 20
   - Determination of cytotoxicity .................................................................................. 21
Objectives of study .........................................................24

3. MATERIALS AND METHODS .................................. 25

4. RESULTS ....................................................................30

5. DISCUSSION ...........................................................39

6. CONCLUSIONS .........................................................44

BIBLIOGRAPHY ..............................................................45
LIST OF TABLES

Table 1. Atomic percentages of elements in commercially available TADs.................. 8

Table 2. Cell viability (MTT) measurements of hPDLF cells subjected to extractions
from TADs for 24 hours ................................................................................................. 31

Table 3. Descriptive statistics for MTT assay results ......................................................... 32

Table 4. ANOVA for MTT assay results ............................................................................. 32

Table 5. Bonferroni adjustment for MTT assay results ..................................................... 33

Table 6. Cell damage (LDH) measurements of hPDLF cells subjected to extractions
from TADs for 24 hours .................................................................................................. 35

Table 7. Descriptive statistics for LDH assay results ......................................................... 36

Table 8. ANOVA for LDH assay results ............................................................................. 36

Table 9. Bonferroni adjustment for LDH assay results..................................................... 37
LIST OF FIGURES

Figure 1. Orthodontic appliance for vitallium screw anchorage ........................................3
Figure 2. Biocompatible temporary anchorage devices ..........................................................4
Figure 3. Biological temporary anchorage devices .................................................................4
Figure 4. Labanauskaite’s classification ................................................................................5
Figure 5. Indirect anchorage .................................................................................................6
Figure 6. Direct anchorage ....................................................................................................6
Figure 7. Components of TADs .............................................................................................8
Figure 8. The different host- material interfaces of mini-screws ...........................................10
Figure 9. Postulated model involving the effects of titanium ions released by biocorrosion on the immune system and the bone metabolism in the pathophysiological mechanisms of aseptic loosening ..................................................12
Figure 10. The classic paradigm: biocompatibility assessment of new materials ..........17

Figure 11. *In vitro* cytotoxicity test procedures ...................................................................20
Figure 12. Schematic representation of *in vitro* cytotoxicity procedures .........................20
Figure 13. MTT cytotoxicity test work flow ........................................................................22
Figure 14. The principles of MTT colorimetric assay .........................................................22
Figure 15. Representative TADs from the four brands used for this experiment ..............25
Figure 16. The TADs incubated in cell culture medium on shaker ...............................26
Figure 17. A 24 well plate with seeded cells during the MTT assay ...............................27
Figure 18. Schematic representation of the principles of LDH assay .................................28
Figure 19. Micro-plate reader (Bio-Tek Power Wave XS2, Winooski, VT) .................28
Figure 20. Morphological changes of the hPDLF cells subjected to the conditioned media from TADs for 24 hours ................................................................................30
Figure 21. Cell viability (MTT) measurement of the hPDLF cells subjected to the conditioned media from TADs for 24 hours ................................................................. 34

Figure 22. Cell damage (LDH) measurement of the hPDLF cells subjected to the conditioned media from TADs for 24 hours.........................................................38
INTRODUCTION

Temporary Anchorage Devices (TADs) are routinely used as a means of skeletal anchorage in contemporary orthodontics. Their multifaceted use has revolutionized our specialty as we can use them as means for direct or indirect anchorage for various types of orthodontic tooth movements. Historically, pure titanium (cpTi) has been used widely as an implant material because of its excellent biocompatibility. However, cpTi has low fatigue strength and alloying it with aluminum and vanadium to form the titanium alloy Ti–6Al–4V helps in overcoming this disadvantage. The corrosion resistance of the alloy Ti-6Al-4V is lower than of cpTi, giving rise to potential metal ion release. There are complications associated with TAD insertion such as localized inflammation, clinical failure of TADs, osteolysis, cutaneous allergic reactions, remote site accumulation, cytotoxicity, hypersensitivity and carcinogenesis (de Morais et al., 2009). Therefore, from the stand points of either biosafety or potential cause of failure of the clinical application of TADs, it is imperative to study the biocompatibility of TADs. Although many studies have been done on dental implants, the biological effects of TADs on oral cells are poorly understood. The aim of our research project was to explore the biological effects of four brands of commercially available TADs on human periodontal ligament fibroblasts (hPDLF). The null hypothesis was that none of the tested TADs will exhibit cytotoxic effects on hPDLF cells.
Anchorage: The backbone of orthodontics

Newton’s third law of motion “Every action has an equal and opposite reaction” has been realized as a truth and holds the key to success in orthodontics. In 1923, Louis Ottofy defined it as “the base against which orthodontic force or reaction of orthodontic force is applied” (Ottofy, 1923). It has been defined as “resistance to unwanted tooth movement” by Daskalogiannakis (Daskalogiannakis, 2009). Different classifications based on anchorage needs have emerged over the years including maximum, moderate, and minimum and so called type A, B, and C (Gianelly et al., 1971; Marcotte 1990; Burstone 1995).

Need for Skeletal anchorage: Historical development

The need for skeletal anchorage in orthodontics increased with the growing numbers of adult patients seeking orthodontic treatment. In addition, complex treatment goals, patients with missing teeth, non-compliance with extra-oral anchorage all added to the growing need to the skeletal anchorage.

The idea of using bone screws dates back to 1945, when Gains forth and Higley placed vitallium screws in the ascending ramus in dogs for canine retraction (Gainsforth BL and Higley LB 1945). The first clinically reported use in humans came from Creekmore and Eklund in 1983 when they inserted vitallium bone screws in the anterior nasal spine to treat a patient with deep bite. An elastomer was used from the screw to intrude the incisors 10 days after the screw was placed (Creekmore and Eklund, 1983). Soon after, in 1985 Jenner used mini-plates successfully as anchorage (Jenner and
Fitzpatrick, 1985). However, the use of mini-implants was not embraced until 1997, when Kanomi described a mini-implant specifically made for orthodontic use (Kanomi, 1997). Soon after in 1998, Costa et al. presented a screw with a bracket like head (Costa et al., 1998). These mini-screws which were temporarily fixed to bone for the purpose of enhancing orthodontic anchorage came to be known as temporary anchorage devices (TADs) and ever since, rapid developments ensued in this area of skeletal anchorage.

Figure 1. Orthodontic appliance for vitallium screw anchorage. (Redrawn from Gainsforth and Higley, 1945)

Classification of TADs

A. Cope’s classification

In 2005, Cope classified TADs as biocompatible and biological in nature. He proposed that ankylosed or dilacerated teeth which are inherently present in the jaws can serve as temporary anchorage devices and are biological TADs which will later be removed. Dental implants and their modifications, fixation screws and wires were
biocompatible temporary anchorage devices.

Figure 2. Biocompatible temporary anchorage devices. Redrawn with permission from Cope JB 2005

Figure 3. Biological temporary anchorage devices. Redrawn with permission from Cope JB 2005
B. Labanauskaite’s classification:

Dental implants placed for the ultimate purpose of supporting a prosthesis, are not considered temporary anchorage devices since they are not removed and discarded after orthodontic treatment.

<table>
<thead>
<tr>
<th>According to the shape and size</th>
<th>According to the implant bone contact</th>
<th>According to the application</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Conical (cylindrical)-miniscrew implants, palatal implants, prosthodontic implants</td>
<td>• Osseointegrated</td>
<td>• Only for orthodontic purposes</td>
</tr>
<tr>
<td>• Miniplate implants</td>
<td>• Nonosseointegrated</td>
<td>• For prosthodontic and orthodontic purposes</td>
</tr>
<tr>
<td>• Disc implants (onplants)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4. Labanauskaite’s classification (Adapted from Labanauskaite B et al 2005)

C. Insertion Modality

- Self-drilling (self-cutting)
- Self – tapping: require pre-drilling at full length

Types of application as anchorage

Direct: Force is applied directly to the tooth/group of teeth from the mini-screw

Indirect: Mini-screw anchors teeth to which the force is applied and prevents movement of these teeth (Papadopoulos MA and Tarawneh F 2007).
Figure 5. Indirect anchorage from a TAD (A) Right buccal with Class II malocclusion. (B) Right buccal with TAD inserted after upper 1st molar distalization. (C) Radiograph showing interproximal location of TAD (D) Upper right canine ligated to the TAD to distalize 1st premolar (From Maino BG et al 2005).

Figure 6. Direct anchorage from TAD to retract anterior teeth. (A) Frontal (B) Right buccal (C) Left buccal (From Maino BG et al 2005).

**Indications and Contraindications**

TADs are now used for a plethora of orthodontic tooth movements including insufficient number of teeth and/or lack of occlusion in the anchorage unit, extrusion or intrusion of single teeth or units of teeth without antagonists; asymmetric tooth movements, unilateral expansion, asymmetric cant correction; retraction and/or intrusion of anterior teeth, mesial or distal movement of molars, proclination of anterior teeth in cases where no posterior anchoring element is available, space closure in maximum anchorage cases, non-compliant cases. With their smaller sizes, wider applications in tooth movements, simpler surgical placement and immediate loading, TADs have become a mainstay in contemporary orthodontics (Costa et al., 1998; Papadopoulos et al., 2007;
Wahl 2008; Yanosky et al., 2008; Reynders et al., 2009; Melsen 2010; Shirck et al., 2011; Yamaguchi et al., 2012). Contraindications to the use include, but are not limited to, patients with systemic conditions such as metabolic bone diseases, immune suppressive therapy, bisphosphonate medication, poor quality bone tissue, hypersensitivity, radiotherapy in the head and neck damage (Melsen, 2005).

**Composition of TADs**

Most commercially available orthodontic mini-implants are made of titanium alloys, primarily Ti-6Al-4V (titanium grade IV-V). Although stainless steel screws were marketed initially, the greater biocompatibility of titanium made it a more attractive option (Maino et al., 2005; Reynders et al., 2009; Proffit WR 5th ed). Titanium has the property of oxidizing in the presence of air and aqueous electrolytes to form a passive titanium dioxide film which contributes to its biocompatibility and corrosion resistance (Velasco-Ortega E et al., 2010), but needs to be alloyed to improve its strength and fatigue resistance (Eliades et al., 2009). The titanium alloy is composed of a fusion of two phases, alpha (6% aluminum) and beta (4% vanadium). Both phases in equilibrium contribute towards advantages of mechanical resilience (alpha phase), good formability and fatigue resistance (beta phase), however this leads to a decrease in the corrosion resistance of the Ti alloy in body fluids (Cotrim-Ferreira et al., 2010).
Table 1. Atomic percentages of elements in commercially available TADs (Malkoc et al., 2012)

<table>
<thead>
<tr>
<th>Brand</th>
<th>C</th>
<th>Al</th>
<th>S</th>
<th>Cr</th>
<th>Fe</th>
<th>Ni</th>
<th>Ti</th>
<th>V</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mini Ortho</td>
<td>6.7</td>
<td>1.34</td>
<td>2.53</td>
<td>18.4</td>
<td>58.1</td>
<td>12.4</td>
<td>-</td>
<td>-</td>
<td>Leone, Italy</td>
</tr>
<tr>
<td>implant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abso Anchor</td>
<td>5.8</td>
<td>8.56</td>
<td>-</td>
<td>0.77</td>
<td>0.84</td>
<td>0.42</td>
<td>83.41</td>
<td>0.18</td>
<td>Dentos, South Korea</td>
</tr>
<tr>
<td>MTN</td>
<td>6.2</td>
<td>8.21</td>
<td>-</td>
<td>0.54</td>
<td>0.49</td>
<td>0.51</td>
<td>83.81</td>
<td>0.15</td>
<td>MTN, Turkey</td>
</tr>
<tr>
<td>IMTEC Ortho</td>
<td>4.56</td>
<td>8.83</td>
<td>-</td>
<td>0.43</td>
<td>0.46</td>
<td>0.49</td>
<td>84.83</td>
<td>0.32</td>
<td>3M Unitek, Okla</td>
</tr>
<tr>
<td>Vector TAS</td>
<td>4.19</td>
<td>8.12</td>
<td>-</td>
<td>0.62</td>
<td>0.47</td>
<td>0.42</td>
<td>86.56</td>
<td>0.13</td>
<td>Ormco, Calif</td>
</tr>
</tbody>
</table>

**Components of TADs**

![Diagram of TAD components](image)

Figure 7. Components of TADs
A successful material to be used as for TAD should have good mechanical properties, corrosion resistance and should be biocompatible.

**Biocompatibility**

Biocompatibility has been defined as “the ability of a material to function in a specific application in the presence of an appropriate host response” by Williams in 1987. This definition rebuked the original philosophy that a material is to be inert in every biological and physicochemical manner to be considered biocompatible. This also helped in defining the basic ideas of biocompatibility and is described below.

a. Interactions at the material–tissue interface affect both the host and the material. Concomitant to the host response to the material, there is a response of the material in the host environment via corrosion, chemical modification, degradation, or other mechanisms. It is a dynamic interaction. It is not static and there are constant influences of aging, local and systemic factors in the host environment and this in turn makes for an ever changing interface where any equilibrium achieved is likely transient and vulnerable to perturbation (Williams, 2008).

b. The reactions at the material–tissue interface are a function of the tissue where the interface is created. The same biomaterial will create a different interface if implanted in the pulp, the bone, the skin. Therefore, favorable material-biological responses in one environment do not assure the same in other environments (Anderson, 2001).

c. Biomaterials are foreign bodies, and biological responses to these materials are characterized by foreign body responses. Avoiding or limiting the foreign body response has been a major goal of material development.
Recently, the research in biocompatibility is looking to customize interactions at the material–tissue interface (Ratner, 2001; Ratner, 2004; Bryant 2004). The aim is to modify the surface of a material to limit nonspecific protein absorption, add peptide sequences to encourage native protein or cell interactions, or provide a three-dimensional structure to encourage matrix formation. This aids in developing materials that degrades by design over time, but additionally directs tissue responses via embedded cells, proteins or drugs. The above developments prompted Williams to update his original definition of biocompatibility “ability of a biomaterial to perform its desired function with respect to a medical therapy, without eliciting any undesirable local or systemic effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial cellular or tissue response to that specific situation, and optimizing the clinically relevant performance of that therapy” (Williams, 2008).

Figure 8. The different host- material interfaces of mini-screws (Adapted from Maino BG et al 2005).
Host – mini-screw interactions

Placement of the implant in an intraoral site induces several phenomena, including reduction of the pH of the early exudative phases, activation of cells including polymorphonuclear granulocytes and macrophages, and the release of proteins, enzymes, and oxidizing agents that might significantly modify the mini-screw implant surface reactivity. The sequence of events after placement includes the selective adsorption of water, \( \text{O}_2^- \), \( \text{HPO}_4^{2-} \), and \( \text{H}_2\text{PO}_4^- \) and the release of Ti as \( \text{Ti(OH)}_4 \) at the outer oxide layer, with oxide growth at the oxide-metal interface. These interactions result in Ti dioxide films having an outermost layer rich in Ti-hydrogen phosphates, along with increased thickness and a more crystalline and insoluble nature. Calcium-phosphate precipitates can subsequently form on this structure, changing the outer oxide layer to complex Ti and calcium phosphates. Retrieval analyses of mini-screws have shown morphologic alterations such as adsorption of iron, calcium, nitrogen, potassium, phosphorus from the surrounding tissue fluids and these are subsequently calcified with precipitation of calcium and phosphorus (Eliades et al., 2009).

Biocorrosion

Metallic biomaterials implanted in the body undergo an inevitable corrosion process releasing undesirable metal ion/corrosion products which may or may not be biocompatible. Titanium alloys release titanium \( \{\text{Ti(IV)}\} \), vanadium and aluminum ions (Scales, 1991; Cadosch et al., 2009). Dissolved metal ions then have a propensity to accumulate in the tissue or get transported to remote organs via systemic circulation.
There are different mechanisms for corrosion in the physiological environment and the most common are:

i. Physicochemical corrosion – Contact of metal surfaces with tissue fluids leading to an electrochemical redox reaction (Steinemann, 1996).

ii. Cellular mechanism – Osteoclast precursors have been shown to grown and differentiate towards mature osteoclasts on stainless steel, titanium and aluminum surfaces and directly corrode the metal and take up the metal ions (Cadosch et al., 2009; Cadosch et al., 2010).

Figure 9. Postulated model involving the effects of titanium ions released by biocorrosion on the immune system and the bone metabolism in the pathophysiological mechanisms of aseptic loosening (Redrawn from Cadosch et al., 2010)
Similar processes likely take place *in vivo*. Ti-6Al-4V alloys used in orthopedics for joint replacements have shown to be susceptible to bio-corrosion in the physiological environment of the human body (Scales, 1991; Cadosch *et al.*, 2009; Cadosch *et al.*, 2010). By the same rationale, Ti-6Al-4V alloys used as TADs would be susceptible to bio-corrosion albeit the shorter duration of use as TADs. It has been observed that titanium ions released as part of corrosion may trigger peri-implantitis which further compromises stability (Mouhyi *et al.*, 2009). Inflammation further enhances corrosion by a positive feedback loop (Messer *et al.* 2010) setting up a vicious cycle similar to that seen in the orthopedic aseptic loosening phenomena (Cadosch *et al.*, 2009, 2010). As the osteoclast precursors differentiate and directly corrode titanium surfaces, this in turn affects bone remodeling and hence affects stability. Pits formed around implant surface from corrosion may intensify the corrosive environment, adversely affect its mechanical properties and may hasten fracture of small diameter mini-screws (Gittens *et al.*, 2011). There is some evidence to show that the presence of acidic solutions and fluoride weaken the stable passive protective dioxide layer on Titanium surfaces making it vulnerable to corrosion (Kononen *et al.*, 1995). A recent in-vitro potentiodynamic corrosion study compared the corrosion properties of three miniscrew implants in artificial saliva with and without fluoride. They measured corrosion currents of 2.7-6.0nA which is relatively low and suggested limited ion release in the oral cavity. They reported that exposure to fluoride increased the corrosion current by impacting the passive oxide layer (Knutson and Berzins, 2012). de Morais *et al.* evaluated the systemic levels of metallic ions, specifically the concentrations of titanium, vanadium and aluminum in rabbits with mini-screw implants at 1-week, 4-weeks, and 12-weeks and confirmed that release of these
metals from the mini-implants occurs with diffusion and accumulation in remote organs such as kidneys, liver and lungs. However, despite the tendency of ion release when using the Ti alloy as TADs, the amounts of metals detected were significantly below the average intake of these elements through food and drink and did not reach toxic concentrations (de Morais et al., 2009). Thus there is uncertainty about the role of corrosion and though it may not reach toxic concentrations locally or systemically, it may be a factor in aseptic loosening, in fractures of small diameter mini-screws and may influence the host- mini-screw interactions with pathways unknown as yet.

The success rate of temporary skeletal anchorage devices has been reported to be relatively low compared with dental implants, with failure rates from 9% to 16.4% (Tseng et al., 2006; Lim et al., 2009). To understand failure, we must first gain a better understanding of stability.

**Stability**

*Primary stability* is essentially created by mechanical retention of the miniscrew in the bone. It is maximal immediately after insertion but declines concomitantly with bone remodeling that occurs around the screw (Proffit WR, Contemporary Orthodontics 5th ed). This has been linked to the tension-compression state generated at the bone-temporary anchorage device interface (Huja, 2005). *Secondary stability* on the other hand is determined by biologic union of screw to surrounding bone and increases over time with the ensuing remodeling. The net sum of primary and secondary stability is *Clinical stability*/*Overall stability*. This decline to minimum at 2 weeks post insertion and eventually stabilizes somewhat greater than initial primary stability at about 6 weeks (Proffit WR, Contemporary Orthodontics 5th ed).
Factors related to primary stability include insertion site characteristics such as cortical density and bone quality. TADs inserted in the maxilla have higher success rates than the mandible with the most favorable position relative to the root being the coronal third. With respect to soft tissues, the attached gingiva is favored followed by mucogingival line. The geometric design of the screw which includes the pitch of screw threads, length, diameter, shape, tip form of the miniscrew are all considerations (Holmgren et al., 1998; Motoyoshi et al., 2007; Baek et al., 2008; Kim et al., 2008; Mesa et al., 2008; Cha, 2010; Wang et al., 2010; Zhang et al., 2010; Manni et al., 2011). In regards to the pitch of the screw threads, tighter thread pitch gives greater contact with cortical bone and increases primary stability. The length is variable between 6-10 mm and diameters range from 1.3-2.0mm. Given that the amount of contact with cortical bone rather than medullary bone is important, screws less than 1.2 mm diameter are avoided and less than 8 mm in length may contribute to decrease in stability as per Crismani et al. Larger diameter will show better primary stability under the application of heavy loads but not otherwise (Crismani et al., 2010). Tapered screws have higher placement torques and primary stability, but no difference in removal torque. This may indicate decrease in strain generated during bone remodeling which in turn may affect secondary stability (Chapman, 1996; Migliorati et al., 2011). Thread forming screw compresses the bone around the thread as it advances and provides better bone to screw contact, especially adapted for alveolar bone. Thread cutting screws have a cutting flute on the tip which improves penetration into denser bone, thus performing better in mandibular ramus and buccal shelf, zygomatic buttress and palate (Yerby et al., 2001). The surface roughness of the threaded part of screw-machined vs. roughened is not a
major influence. Preexisting soft tissue inflammation or lack of immaculate hygiene predisposing to inflammation can compromise the stability. Though root proximity is not a key factor in long term stability, it is advisable to avoid contact. The operator technique and inadvertent micromotion have also been implicated in failure of miniscrews. However, immediate or early loading of mini-screws has not shown to be a cause of failure. In addition, longer healing periods have not shown to provide greater stability at forces of up to 200 cN. Maximum insertion torque has emerged as key factor to primary stability of screws (Motoyoshi et al., 2006; Motoyoshi et al., 2007; Lim et al., 2008; Cha, 2010; Suzuki et al., 2011). Despite considering factors of insertion site, meticulous placement and hygiene, geometric design of screws and loading considerations, miniscrews still are prone to loss of stability which makes it essential to analyze host-miniscrew interactions.
Measuring biological responses – In Vitro testing

Figure 10. The Classic Paradigm: Biocompatibility assessment of new materials (Adapted from Autian, 1970)

This stepwise testing was proposed by Autian and entailed testing a new material first with \textit{in vitro} tests. This was a screening tool and materials that ‘passed’ the \textit{in vitro} tests were subsequently tested in animals and clinical trials. Of critical value is the fact that each level of test eliminated unsuitable materials from further testing (Autian, 1970).

By definition, \textit{in vitro} tests occur outside an organism, in a vessel of some sort, using cultures of cells or cell constituents. It is one of the most fundamental ways of testing for biological responses. They are to be differentiated from \textit{ex vivo} tests which use an intact tissue or organ that is maintained for a short time (usually < 24 h) in a culture vessel. In their most sophisticated form, \textit{in vitro} tests use multiple cells, barriers, or special culture conditions to attempt to replicate conditions \textit{in vivo}. 
The primary strengths of *in vitro* tests are the ability to control the environment of the cells and their interface with materials and the ability to measure cell response in detail and with precision. Thus they lend themselves well to identify detailed mechanisms of cellular response. In addition, they are faster, less expensive, more reproducible, and more feasible than other types of tests. However, *in vitro* tests may suffer from a lack of relevance to the clinical use of materials and this is an important consideration (Wataha, 2012).

However, adaptation of *in vitro* tests has provided some successes in correlating with the clinical performance of materials. As an example, early *in vitro* tests of ZOE cements predicted acute, severe pulpal toxicity but this was not in echoed in the clinical setting, where it was being used successfully under cavity preparations and *in vivo* pulpal studies verified a relatively low toxicity. The use of a dentin barrier in *in vitro* models reduced the apparent toxicity of ZOE. This created doubts about the reliability of interpreting in vitro test results to the clinical situation and a belief that *in vitro* tests might be more useful if they could be constructed with more appropriate clinical relevance (Wennenburg, 1978; Langleand, 1983).

**Principles of In Vitro Cytotoxicity testing: ISO 10993-5:2009(E)**

a. Sample and controls
- Test sample- Material / device or extract there of that is subjected to biological /chemical testing or evaluation.
- Positive control – produces reproducible cytotoxic response when tested in accordance with ISO 10993.
- Negative control – Does not produce cytotoxic response and helps in
demonstrating the background response of cells to a stimulus.

- Blank – Extraction vehicle not containing the test sample but retained in the vessel identical to that containing test sample. Aids in assessing possible confounding effects due to extraction vessel, vehicle and extraction process.

b. Extraction vehicles for mammalian cell assays – Culture medium with serum is preferred since it supports cellular growth and is able to extract both ionic and non-ionic compounds.

c. Choice of serum depends on cell type. Serum/ proteins may bind to some extractable and this needs to be considered

d. Extractions should be done in sterile, chemically inert containers using aseptic techniques. For culture medium with serum the temperature should be $(37 \pm 1) ^\circ$ Celsius to ensure stability of medium and serum.

e. Any processing of extract by means of filtration, centrifuging should be documented in final reporting. Avoid changing the pH of the extract.

f. Cell lines – Established cell lines from recognizable repositories.

Culture medium- Should meet growth requirements of the cells. Antibiotics may be added as long as they do not influence the assays. pH- 7.2-7.4 maintained.
## In Vitro Cytotoxicity test procedures

<table>
<thead>
<tr>
<th>Tests on extracts</th>
<th>Tests by direct contact</th>
<th>Tests by indirect contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Extract added to cell suspensions</td>
<td>• Cell suspension directly exposed to test sample</td>
<td>• Agar diffusion</td>
</tr>
<tr>
<td>• Allows qualitative and quantitative assessment</td>
<td>• Allows qualitative and quantitative assessment of cytotoxicity</td>
<td>• Filter diffusion</td>
</tr>
<tr>
<td>• Can be performed on original extract or dilution series of the same</td>
<td>• Undue movement of specimens can cause physical trauma to the cells</td>
<td>• Qualitative assessment of cytotoxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Use of appropriate staining procedures to determine cytotoxicity</td>
</tr>
</tbody>
</table>

Figure 11. *In Vitro* cytotoxicity test procedures (Adapted from ISO 10993-5:2009(E)).

Figure 12. Schematic representation of *in vitro* cytotoxicity procedures. (Adapted from ISO 10993-5:2009(E))
**Determination of Cytotoxicity ISO 10993-5:2009(E)**

A. Qualitative evaluation

- Useful for screening purposes
- Cytochemical staining may be used and cells examined microscopically.
- Assess changes in general morphology, vacuolization, cell lysis, membrane integrity or lack thereof. These may be recorded descriptively or numerically and compared with reference tables provided.

B. Quantitative evaluation

- Preferred means of determination
- Measure cell death, inhibition of cell growth / proliferation or colony formation.
  These tests, utilize number of cells, release of vital dyes, proteins, enzymes or any measurable parameters to quantify the results.
- Reduction of cell viability by more than 30% is considered to be a cytotoxic effect

- Protocols

  ➢ Neutral red uptake ( NRU ) uptake cytotoxicity test
  ➢ Colony formation cytotoxicity test
  ➢ MTT cytotoxicity test
  ➢ XTT cytotoxicity test
## Procedure

- **00:00**
  - Seed 96 well plates: 1 × 10^4 cells/100 µl MEM culture medium/well
  - Incubate (37°C / 5% CO₂ / 22 h to 26 h)

- **24:00**
  - Remove culture medium
  - Treat with > or = 4 concentrations of test sample extract in treatment medium (100 µl)
  - Incubate (37°C / 5% CO₂ / 24 h)

- **48:00**
  - Microscopic evaluation of morphological alterations
  - Remove culture medium
  - Add 50 µl MTT solution
  - Incubate (37°C / 5% CO₂ / 2 h)

- **51:00**
  - Remove MTT solution
  - Add 100 ml isopropanol to each well-sway plate
  - Detect absorption at 570 nm (reference 650 nm) after 30 minutes

Figure 13. MTT cytotoxicity test work flow

![Figure 14. The Principle of MTT colorimetric assay](image)
Cytotoxicity tests of different orthodontic materials from stainless steel wires; latex and non-latex elastics; archwires; esthetic, metallic and nickel free brackets have been undertaken with variable methodologies but in keeping with the basic principles of cytotoxicity testing (David A 2004; Hanson M 2004; Retamoso LB et al 2012; Oh KT 2005).

Cytotoxicity studies relevant to orthodontic mini-screws have used titanium alloy discs (Ti-6Al-4V) subjected to different surface treatments such as nitric oxide passivation and sand blasting and have reported no cytotoxicity to the mouse or human fibroblasts (Velasco-Ortega E et al., 2010). Interestingly, another study using discs observed a transient decrease in cell viability of MC3T3-E1 osteoblasts with the titanium alloy discs at day 4, followed by a partial restoration around 8 days and total restoration after 15 days in the culture. This pattern was noted in the discs irrespective of any specific surface treatment. They concluded that this was a temporary alteration of cell viability to the chemical composition (Citeau et al., 2005). Given that different manufacturers have trace elements added to the generic Ti-6Al-4V alloys along with colored coatings and surface treatments for color coding and passivation treatments, it is clinically relevant to use commercially available mini-screws.

A recent study using commercially available mini-implants, incubated the TADs in Dulbecco’s modified eagle’s culture medium for 72 hours according to the 2009 version of ISO 10993-5 standards and used a real time cell analyzer to assess cytotoxicity of released bioactive components from TADs on human gingival fibroblasts and mouse osteoblast cells over a period of 190 hours. They observed that the stainless steel containing TADs caused a significant decrease in mouse osteoblast viability. The
remaining TADs were titanium alloys of similar composition – yet two of them showed no adverse effects on MC3T3-E1 cells at 190 hours while the remaining two caused a significant decrease. None of the above tested TADs showed adverse effects on human fibroblasts (Malkoc et al., 2012).

Generally, TADs are likely to be in the oral cavity for 6-8 months and hence if they would release any bioactive components, it may accumulate over time to increase the dosage of bioactive component exposed to adjacent cells.

**Objectives of Study**

The objective of our study was to test the cytotoxicity of four brands of commercially available TADs. Our null hypothesis was that TADs and their extracts do not cause cytotoxic effects on human periodontal ligament fibroblasts (hPDLF) according to ISO standards. Since TADs remain in the oral cavity for an extended time period, we subjected the hPDLF cells to the conditioned medium collected from the TADs incubated in complete cell culture medium for 30 days. As endpoints, we observed the morphological changes of the cells, and measured the cell viability (via MTT assay) and cell damage (via LDH assay).
MATERIALS AND METHODS

Six of each of the four commercially available brands of TADs (Aarhus, American Orthodontics; Dual Top, RMO; Vector TAS, ORMCO; Unitek TAD, 3M UNITEK) were used in this study. In an effort to standardize the test products, all the chosen TADs had relatively similar length and diameter (Fig 14). All the TADs were used for the cytotoxicity tests directly from their sterile surgical packages, except for the product from American Orthodontics which was autoclaved prior to use due to its unspecified sterile condition. According to the ISO 10993-5 standards, cytotoxicity can be tested by contact (direct) or extraction (indirect) means. Due to the complicated surface topography of TADs, we chose to use the extraction method, that is, to incubate the TADs in cell culture medium for certain time and use the conditioned medium for cytotoxicity testing.

![Figure15. Representative TADs from the four brands used for the experiment](image)
In this study, twenty-four TADs of the four kinds (n=6 for each brand) were individually submerged in 8 mL alpha-minimal essential medium (α-MEM) with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (10,000 units of penicillin and 10 mg of Streptomycin in 0.9% NaCl), and sealed in 15mL volume test tubes. To mimic the clinical scenario where the TADs are placed intra-orally and exposed to the flow of saliva, the test tubes were constantly shaken at a speed of 1.5 round per minute (rpm) to simulate physiological salivary flow (Zhou 2010) at 37ºC in incubator for 30 days. The speed of shaking was determined based on our previous study (Zhou 2010). By the end of shaking for 30 days, the conditioned media (CM) were collected for cytotoxicity tests. In addition to the experimental groups, a control group (n=6) was set under the same experimental condition without TADs.

Figure 16. The TADs incubated in cell culture medium on shaker
Figure 17. A 24 well plate with seeded cells during the MTT assay

The cell source, hPDLF cells #2630 (Science Cell Research Laboratories, Inc. Carlsbad, CA) were grown in the same type of cell culture medium as used for incubating TADs in a humidified atmosphere of 5% CO₂, 95% air at 37ºC. To test cytotoxicity, the cells (5X10⁴ cells/ml/well) were seeded in 24-well plates for 24 hours and then treated by the CM for 24 hours. As positive control, 0.1% Triton-100 (Sigma, St. Louis, MO) was used to generate cell damage and death, while the cells treated with the CM without TADs were used as negative control. By the end of 24 hours of treatment, morphological changes as well as cell damage and viability were examined.

The cell shape and size were observed under the microscope (Nikon Eclipse Ti-S, Nikon Instruments Inc, America), and digital images were taken from all the groups in this experiment under the magnification of 20.

LDH Assay

Lactate dehydrogenase (LDH) is an enzyme located in the cytoplasm and is released into surrounding culture medium upon cell damage or lysis. LDH activity in the culture medium can be used as an indicator of cell membrane integrity and hence of cytotoxicity (Haslam, 2000, Wolterbeek, 2005, David, 2004). Quantity of LDH in CM at 24 hours was determined following the assay protocol of Cayman LDH Cytotoxicity
Assay Kit (Life Technologies Corporation, Grand Island, NY). The absorbance was read at 490nm with a plate reader (Bio-Tek power wave XS2, Winooski, VT). Blank LDH levels were subtracted from insult LDH value.

Figure 18. Schematic representation of the principles of LDH assay

Figure 19. Micro-plate reader. Bio-Tek power wave XS2, Winooski, VT

MTT assay

The MTT assay is based on the measurement of cell viability via metabolic
activity. Yellow water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid) is metabolically reduced in viable cells to a blue – violet
insoluble formazan. The number of viable cells correlates with the color intensity
determined by photometric measurements (Scudiero, 1988; Sjögren, 2000). The reduction
of MTT is thought to occur mainly in the mitochondria through the action of succinate
dehydrogenase, therefore providing a measurement of mitochondrial function. The
hPDLF cells damage was thus quantified by measurement of the reduction of MTT to
produce dark blue formazan crystals in accordance with the test protocol in MTT kit
(Sigma Aldrich, St. Louis, MO). To make the measurement, 75 µl solution MTT was
added at 24 hours and after 3 hours of incubation, the medium was removed and the
resulting MTT formazan crystals were dissolved by the addition of MTT solvent. The
assay of the formation of formazan was performed by measuring the amount of reaction
product by absorbance change using the micro-plate reader at a wavelength of 570nm.
Each plate included three blank wells containing complete culture medium without cells

Statistical analysis

All the MTT and LDH assay data (optical densities) were exported in excel file.
All the data were expressed as means ± standard deviation (n=6). Statistically, one-way
ANOVA was used to determine the difference between all the experimental groups and
the control, while Bonferroni adjustment was applied to find out the difference between
any two of the four TAD groups. A $P$ value less than 0.05 was considered significant
(SPSS, version 11.10, Chicago).
RESULTS

Changes in cell morphology (shape, size and polarity) correspond to the metabolic status of the cells. When cells are injured or undergoing cell death, it can be found that the integrity of the cell membrane is partially or totally lost, and cells usually shrink in size and lose their polarity, ultimately disintegrating. Therefore, these morphological changes can be used to indicate cell damage or death. In our study, the fibroblasts in the negative control and TAD groups appeared to be spindle shaped cells with no distinct abnormal changes while the fibroblasts exposed to 0.1% Triton -100 lost their normal spindle shape and became rounded.

Figure 20. Morphological changes in hPDLF cells subjected to the conditioned media from TADs for 24 hours
Six of each of the commercially available TADs were submerged and shaken with the MEM at a rate of 1.5 rpm for 30 days. We expected the TADs to release metal ions/cytotoxic products over time and then used the extracted conditioned medium to expose the hPDLF and perform tests for cytotoxicity.

The MTT cytotoxicity test (ISO 10993-5:2009) quantitatively measures the cell viability. In accordance with this, our positive control group exposed to 0.1% Triton-100, had the lowest MTT value while the negative control i.e. control conditioned medium without any TAD had the highest MTT levels. There was a significant difference amongst all TADs group along with the negative control as one group in comparison with the positive control ($P = 0.000$). Interestingly, among the four TAD groups, the 3M UNITEK product showed a marginal increase in cytotoxicity (less cell viability) than the negative control ($P = 0.047$)

Table 2. Cell viability (MTT) measurements of hPDLF cells subjected to extracts from TADs

<table>
<thead>
<tr>
<th>Samples</th>
<th>Negative control</th>
<th>Positive control</th>
<th>RMO</th>
<th>ORMCO</th>
<th>AO</th>
<th>3M</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.494</td>
<td>0.198</td>
<td>0.326</td>
<td>0.309</td>
<td>0.324</td>
<td>0.332</td>
</tr>
<tr>
<td>2</td>
<td>0.449</td>
<td>0.159</td>
<td>0.332</td>
<td>0.315</td>
<td>0.372</td>
<td>0.390</td>
</tr>
<tr>
<td>3</td>
<td>0.470</td>
<td>0.121</td>
<td>0.372</td>
<td>0.449</td>
<td>0.360</td>
<td>0.368</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>0.383</td>
<td>0.304</td>
<td>0.285</td>
<td>0.316</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>0.415</td>
<td>0.377</td>
<td>0.476</td>
<td>0.254</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td>0.320</td>
<td>0.421</td>
<td>0.532</td>
<td>0.333</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>0.47 ± 0.023</td>
<td>0.16 ± 0.039</td>
<td>0.36 ± 0.038</td>
<td>0.36 ± 0.063</td>
<td>0.39 ± 0.094</td>
<td>0.33 ± 0.050</td>
</tr>
</tbody>
</table>
### Table 3. Descriptive statistics for MTT assay results

<table>
<thead>
<tr>
<th>MTT</th>
<th>N</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>Std. Error</th>
<th>95% Confidence Interval for Mean</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.000</td>
<td>3</td>
<td>.15933</td>
<td>.0385011</td>
<td>.022296</td>
<td>.053691 - .254395</td>
<td>.1210</td>
<td>.1980</td>
</tr>
<tr>
<td>1.000</td>
<td>3</td>
<td>.47100</td>
<td>.0225167</td>
<td>.013000</td>
<td>.415086 - .526934</td>
<td>.4480</td>
<td>.4940</td>
</tr>
<tr>
<td>2.000</td>
<td>6</td>
<td>.35800</td>
<td>.0379842</td>
<td>.0155070</td>
<td>.318138 - .397862</td>
<td>.3200</td>
<td>.4150</td>
</tr>
<tr>
<td>3.000</td>
<td>6</td>
<td>.36250</td>
<td>.0326965</td>
<td>.0255965</td>
<td>.306702 - .428298</td>
<td>.3040</td>
<td>.4490</td>
</tr>
<tr>
<td>4.000</td>
<td>6</td>
<td>.39150</td>
<td>.0339637</td>
<td>.0338362</td>
<td>.328385 - .490115</td>
<td>.2850</td>
<td>.5320</td>
</tr>
<tr>
<td>5.000</td>
<td>6</td>
<td>.33217</td>
<td>.0469059</td>
<td>.0191493</td>
<td>.282342 - .381391</td>
<td>.2540</td>
<td>.3900</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>.35187</td>
<td>.033003</td>
<td>.0170342</td>
<td>.317028 - .388706</td>
<td>.1210</td>
<td>.6320</td>
</tr>
</tbody>
</table>

### Table 4. ANOVA analysis of MTT assay results

<table>
<thead>
<tr>
<th>MTT</th>
<th>Sum of Squares</th>
<th>df</th>
<th>Mean Square</th>
<th>F</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between Groups</td>
<td>.166</td>
<td>5</td>
<td>.033</td>
<td>9.290</td>
<td>.000</td>
</tr>
<tr>
<td>Within Groups</td>
<td>.086</td>
<td>24</td>
<td>.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>.252</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5. Bonferroni adjustment for MTT assay results

<table>
<thead>
<tr>
<th>MTT Bonferroni</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower Bound</td>
</tr>
<tr>
<td>Mean Difference (I-J)</td>
<td>Std. Error</td>
</tr>
<tr>
<td>0.000</td>
<td>1.0000</td>
</tr>
<tr>
<td>2.0000</td>
<td>-0.1986667*</td>
</tr>
<tr>
<td>3.0000</td>
<td>-0.2031667*</td>
</tr>
<tr>
<td>4.0000</td>
<td>-0.2321667*</td>
</tr>
<tr>
<td>5.0000</td>
<td>-0.1723333*</td>
</tr>
<tr>
<td>1.0000</td>
<td>0.0000</td>
</tr>
<tr>
<td>2.0000</td>
<td>-0.1130000</td>
</tr>
<tr>
<td>3.0000</td>
<td>-0.1085000</td>
</tr>
<tr>
<td>4.0000</td>
<td>-0.0795000</td>
</tr>
<tr>
<td>5.0000</td>
<td>-0.1389333*</td>
</tr>
<tr>
<td>2.0000</td>
<td>0.0000</td>
</tr>
<tr>
<td>1.0000</td>
<td>0.1130000</td>
</tr>
<tr>
<td>3.0000</td>
<td>-0.0045000</td>
</tr>
<tr>
<td>4.0000</td>
<td>-0.0335000</td>
</tr>
<tr>
<td>5.0000</td>
<td>0.0258333</td>
</tr>
<tr>
<td>3.0000</td>
<td>0.0000</td>
</tr>
<tr>
<td>1.0000</td>
<td>-0.1085000</td>
</tr>
<tr>
<td>2.0000</td>
<td>0.0450000</td>
</tr>
<tr>
<td>4.0000</td>
<td>-0.0290000</td>
</tr>
<tr>
<td>5.0000</td>
<td>0.0303333</td>
</tr>
<tr>
<td>4.0000</td>
<td>0.0000</td>
</tr>
<tr>
<td>1.0000</td>
<td>-0.0795000</td>
</tr>
<tr>
<td>2.0000</td>
<td>0.0350000</td>
</tr>
<tr>
<td>3.0000</td>
<td>0.0290000</td>
</tr>
<tr>
<td>5.0000</td>
<td>0.0593333</td>
</tr>
<tr>
<td>6.0000</td>
<td>0.0000</td>
</tr>
<tr>
<td>1.0000</td>
<td>-0.1389333*</td>
</tr>
<tr>
<td>2.0000</td>
<td>-0.2583333</td>
</tr>
<tr>
<td>3.0000</td>
<td>-0.0303333</td>
</tr>
<tr>
<td>4.0000</td>
<td>-0.0593333</td>
</tr>
</tbody>
</table>

* The mean difference is significant at the 0.05 level

Note: 0 – positive control, 1 – negative control, 2 – RMO, 3 – ORMCO, 4 – AO, 5 – 3M
As one can see, the conditioned media were harvested after 30 days of merging all the 4 brands of TADs in cell culture media. Afterwards, the hPDLF cells were treated with conditioned media from TADs for 24 hours. The cell viabilities were tested using MTT method. The positive control group was treated by Triton-100 (according to the assay kit manufacturer’s instructions), showing the lowest MTT value of 0.16 ± 0.039 (n=3) (the lower the MTT value, the less viable cells). Negative control was the control conditioned medium without any TAD, showing the highest value of 0.47 ± 0.023 (n=3). All four brands of TADs together with the negative control showed significant different MTT results in comparison to the positive control ($P = 0.000$). 3M UNITEK product
showed a marginal increase in cytotoxicity (less cell viability) than the negative control ($P = 0.047$).

Lactate dehydrogenase (LDH) is a cytoplasmic enzyme naturally present in all cells and releases into cell culture supernatant when the cellular plasma membrane is damaged or upon cell lysis (David, 2004; Han, 2011). LDH activity in the culture medium can be used as an indicator of cell membrane integrity and a measurement of cytotoxicity. In our study, the positive control group cells treated by 0.1% Triton-100, showed the highest released LDH concentration (0.4 ± 0.024) and thus high cytotoxicity while the negative control resulted in the lowest LDH level (0.17 ± 0.012) as expected. All four TAD groups together with the negative control showed significantly lower LDH levels than the positive control ($P = 0.000$). There was no significant difference amongst the different brands of TADs ($P > 0.05$).

Table 6. Cell damage (LDH) measurements of hPDLF cells subjected extracts from TADs for 24 hours

<table>
<thead>
<tr>
<th>Samples</th>
<th>Negative control</th>
<th>Positive control</th>
<th>RMO</th>
<th>ORMCO</th>
<th>AO</th>
<th>3M</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.169</td>
<td>0.379</td>
<td>0.228</td>
<td>0.162</td>
<td>0.165</td>
<td>0.167</td>
</tr>
<tr>
<td>2</td>
<td>0.164</td>
<td>0.405</td>
<td>0.228</td>
<td>0.154</td>
<td>0.171</td>
<td>0.156</td>
</tr>
<tr>
<td>3</td>
<td>0.186</td>
<td>0.427</td>
<td>0.177</td>
<td>0.162</td>
<td>0.184</td>
<td>0.208</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>0.167</td>
<td>0.155</td>
<td>0.165</td>
<td>0.168</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>0.157</td>
<td>0.153</td>
<td>0.154</td>
<td>0.162</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td>0.180</td>
<td>0.167</td>
<td>0.161</td>
<td>0.174</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>0.17 ± 0.012</td>
<td>0.40 ± 0.024</td>
<td>0.19 ± 0.031</td>
<td>0.16 ± 0.006</td>
<td>0.17 ± 0.010</td>
<td>0.17 ± 0.018</td>
</tr>
</tbody>
</table>
Table 7. Descriptive statistics of LDH assay results

<table>
<thead>
<tr>
<th>LDH24</th>
<th>N</th>
<th>Mean</th>
<th>Std Deviation</th>
<th>Std Error</th>
<th>95% Confidence Interval for Mean</th>
<th>Lower Bound</th>
<th>Upper Bound</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.000</td>
<td>3</td>
<td>4.03333</td>
<td>0.0242710</td>
<td>0.0140129</td>
<td>0.343041</td>
<td>.463628</td>
<td>.5785</td>
<td>4.270</td>
<td>1.0000</td>
</tr>
<tr>
<td>1.000</td>
<td>3</td>
<td>1.72500</td>
<td>0.0115328</td>
<td>0.0065583</td>
<td>0.143852</td>
<td>.201148</td>
<td>.1835</td>
<td>1.855</td>
<td></td>
</tr>
<tr>
<td>2.000</td>
<td>6</td>
<td>1.89063</td>
<td>0.0306260</td>
<td>0.0125947</td>
<td>0.165733</td>
<td>.221433</td>
<td>.1585</td>
<td>1.2275</td>
<td></td>
</tr>
<tr>
<td>3.000</td>
<td>6</td>
<td>1.59500</td>
<td>0.0058633</td>
<td>0.0023202</td>
<td>0.152536</td>
<td>.164464</td>
<td>.1530</td>
<td>1.1670</td>
<td></td>
</tr>
<tr>
<td>4.000</td>
<td>6</td>
<td>1.56417</td>
<td>0.0095771</td>
<td>0.0040731</td>
<td>0.155946</td>
<td>.178897</td>
<td>.1540</td>
<td>1.1025</td>
<td></td>
</tr>
<tr>
<td>5.000</td>
<td>6</td>
<td>1.72333</td>
<td>0.0104328</td>
<td>0.0075251</td>
<td>0.152983</td>
<td>.191677</td>
<td>.1590</td>
<td>1.2000</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>1.94850</td>
<td>0.0734537</td>
<td>0.0134108</td>
<td>0.167422</td>
<td>.222278</td>
<td>.1530</td>
<td>.4270</td>
<td></td>
</tr>
</tbody>
</table>

Table 8. ANOVA analysis of LDH assay results

<table>
<thead>
<tr>
<th>LDH24</th>
<th>Sum of Squares</th>
<th>df</th>
<th>Mean Square</th>
<th>F</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between Groups</td>
<td>.148</td>
<td>5</td>
<td>.030</td>
<td>83.007</td>
<td>.000</td>
</tr>
<tr>
<td>Within Groups</td>
<td>.009</td>
<td>24</td>
<td>.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>.156</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 9. Bonferroni adjustment of LDH assay results

<table>
<thead>
<tr>
<th>(i) group (J) group</th>
<th>Mean Difference (i-J)</th>
<th>Std. Error</th>
<th>Sig.</th>
<th>Lower Bound</th>
<th>Upper Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>.0000 .0000</td>
<td>.2308333</td>
<td>.0154141</td>
<td>.000</td>
<td>.1806082</td>
<td>.2810582</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>.2142500</td>
<td>.0133490</td>
<td>.000</td>
<td>.1707548</td>
<td>.2577462</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>.2488333</td>
<td>.0133490</td>
<td>.000</td>
<td>.2013378</td>
<td>.2883308</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>.2369167</td>
<td>.0133490</td>
<td>.000</td>
<td>.1934208</td>
<td>.2804138</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>.2310000</td>
<td>.0133490</td>
<td>.000</td>
<td>.1875048</td>
<td>.2744968</td>
</tr>
<tr>
<td>1.0000 .0000</td>
<td>-.2308333</td>
<td>.0154141</td>
<td>.000</td>
<td>-.2810582</td>
<td>-.1806082</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>-.0165833</td>
<td>.0133490</td>
<td>.000</td>
<td>-.2013378</td>
<td>-.026913</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>.0140000</td>
<td>.0133490</td>
<td>.000</td>
<td>.0294968</td>
<td>.0574968</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>.0060833</td>
<td>.0133490</td>
<td>.000</td>
<td>.0374138</td>
<td>.0495008</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>.0018667</td>
<td>.0133490</td>
<td>.000</td>
<td>.0433308</td>
<td>.0436638</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>-.2142500</td>
<td>.0133490</td>
<td>.000</td>
<td>-.2677468</td>
<td>-.1707548</td>
</tr>
<tr>
<td>1.0000 .0000</td>
<td>.0165833</td>
<td>.0133490</td>
<td>.000</td>
<td>.0286138</td>
<td>.0600808</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>.0305833</td>
<td>.0108994</td>
<td>.147</td>
<td>.0049318</td>
<td>.0680988</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>.0226667</td>
<td>.0108994</td>
<td>.726</td>
<td>-.0128488</td>
<td>.0581818</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>.0167500</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0493488</td>
<td>.0262248</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>-.2448333</td>
<td>.0133490</td>
<td>.000</td>
<td>-.2083308</td>
<td>-.2013378</td>
</tr>
<tr>
<td>1.0000 .0000</td>
<td>-.0140000</td>
<td>.0133490</td>
<td>.000</td>
<td>-.0574968</td>
<td>.0294968</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>-.0306833</td>
<td>.0108994</td>
<td>.147</td>
<td>-.0660988</td>
<td>.0493188</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>-.0079167</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0434318</td>
<td>.0275968</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>-.0138333</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0493488</td>
<td>.0262248</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>-.2369167</td>
<td>.0133490</td>
<td>.000</td>
<td>-.2804138</td>
<td>-.1934208</td>
</tr>
<tr>
<td>1.0000 .0000</td>
<td>.0060833</td>
<td>.0133490</td>
<td>.000</td>
<td>.0495808</td>
<td>.0374138</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>-.0226667</td>
<td>.0108994</td>
<td>.726</td>
<td>-.0598188</td>
<td>.0128488</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>.0079167</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0275968</td>
<td>.0434318</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>-.0059167</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0414318</td>
<td>.0295988</td>
</tr>
<tr>
<td>5.0000 .0000</td>
<td>-.2310000</td>
<td>.0133490</td>
<td>.000</td>
<td>-.2744968</td>
<td>-.1875048</td>
</tr>
<tr>
<td>1.0000 .0000</td>
<td>-.0018667</td>
<td>.0133490</td>
<td>.000</td>
<td>-.0436638</td>
<td>.0433308</td>
</tr>
<tr>
<td>2.0000 .0000</td>
<td>.0167500</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0522648</td>
<td>.0187648</td>
</tr>
<tr>
<td>3.0000 .0000</td>
<td>.0138333</td>
<td>.0108994</td>
<td>.100</td>
<td>-.0216618</td>
<td>.0493488</td>
</tr>
<tr>
<td>4.0000 .0000</td>
<td>.0059167</td>
<td>.0108994</td>
<td>.100</td>
<td>.0295988</td>
<td>.0414318</td>
</tr>
</tbody>
</table>

* The mean difference is significant at the 0.05 level.

**Note:** 0 – positive control, 1 – negative control, 2 – RMO, 3 – ORMCO, 4 – AO, 5 – 3M
Figure 22: Cell damage (LDH) measurement of the hPDLF cells subjected to the conditioned media from TADs for 24 hours.

As we can see, the conditioned media were harvested after 30 days of merging all the 4 brands of TADs in cell culture media. Afterwards, the hPDLF cells were treated with conditioned media from TADs for 24 hours. The cytotoxicity was tested by measuring LDH release. The positive control group was treated by Triton-100, showing the highest LDH concentration. Negative control was the control conditioned medium without any TAD, showing the lowest LDH level. All four brands of TADs together with the negative control showed significantly different LDH levels from the positive control ($P = 0.000$). There was no significant difference amongst the TADs in relation to LDH assay results ($P > 0.05$).
DISCUSSION

*In vitro* cytotoxicity tests are advised by the International Standard Organization (ISO) to evaluate acute cytotoxicity of a material (ISO 10993-5:2009) but they can also aid in better understanding of the pathogenicity of sub-acute effects of cytotoxicity. Compared to animal studies and clinical approaches, these tests are generally simple, inexpensive, and can be performed under controlled conditions (Mockers *et al.*, 2002; Samara *et al.*, 2011). Ideally, cytotoxicity tests should be done on the same type of tissue that the tested compounds will be exposed to and efforts should be made to simulate *in vivo* conditions as much as possible.

Cell cultures used for dental material toxicity testing are also advantageous since they are relatively easy to perform, cost effective and easier to control in contrast to animal experiments (Malkoc *et al.*, 2012). Since TADs are inserted into alveolar bone in close proximity to periodontal ligament and gingiva, it was decided to use the major cellular component of the human periodontal ligament - the spindle shaped fibroblasts (Fundamentals of Periodontics 2nd ed.) to test the cytotoxicity. According to the ISO standards, cell lines have advantages over primary cells in testing cytotoxicity because they are morphologically and physiologically more homogenous than primary cultures and thus can be utilized reliably and reproducibly (Hernandez –Sierra *et al.*, 2011). Therefore, in this study, we chose an established cell line hPDLF #2630 to test the cytotoxicity.

We used commercially available mini-implants rather than using Ti-6Al-4V discs (Watanabe *et al.*, 2004), because it is more clinically relevant to use the product which is used intra-orally. In addition, we submerged the TADs in the conditioned medium for 720
hours (30 days) in a water bath shaker (1.5 rpm) to further simulate normal salivary flow rate and mimic *in vivo* conditions favoring bio-corrosion and release of metal ions over a period of time.

Apart from the MTT assay analysis, no significant differences were seen among the tested TADs for observed cell morphology changes and LDH assay analysis. This is not surprising since all these TADs have similar composition (Ti-6Al-4V), although the exact atomic percentages of the tested TADs were not provided by the manufacturers. An interesting finding in our study was that among the four TAD groups, only the 3M UNITEK TAD showed a slight less cell viability than the negative control (*P* = 0.047) based on the MTT assay analysis. The explanation to this may lie in further evaluating biocorrosion. A recent corrosion study examined mini-screws from 3M Unitek, Ormco and American Orthodontics in artificial saliva and noted a subtle but not significant difference in the passivity of the 3M Unitek mini-screws at potentials above 0.3 V. It was noted that the 3 M Unitek had a comparatively less stable passive layer at potentials above 0.3 V (Knutson 2012) and a less stable passive oxide layer typically is associated with greater corrosion rate (Bohni 2005). The authors observed that the silver/grey colored Unitek TADs may suggest a thinner oxide layer in contrast to the American Orthodontics and Ormco mini-screws which were blue and pink colored. TADs may be subjected to different surface treatments accounting for the variability in oxide layer. It is of value to consider however that some manufacturers provide color-coded options to differentiate sizes and locations for use and so not all mini-screws from a particular manufacturer may perform the same (Knutson K, Berzins D 2012). In our study, both 3M and RMO had a similar color but 3M still had a slightly less cell viability based on MTT
analysis. American Orthodontics with the blue color in the study by Knutson et al., had a significantly more noble open circuit potential (P < 0.05) compared with the others. Also, acidic solutions and fluorine tends to decrease corrosion resistance by decreasing the stability of the passive layer (Kononen, 1995). Although our TADs were submerged in culture medium instead of artificial saliva, the same medium was used for all test products and hence this additive variable was eliminated in our study design.

Despite similar composition, TADs have shown to cause variable cellular reactions on different cell types in previous studies. In another in vitro study, Malkoc et al. observed that the same Ti-6Al-4V alloy in MTN and Vector TAS (Ormco) significantly decreased the MC3T3-E1 (mouse osteoblasts) cell viability at 190 hours in contrast to AbsoAnchor (Dentos, South Korea) and IMTEC Ortho (3M Unitek, Europe). The Leone mini-screw (Leone, Italy) which contains stainless steel had the most significant decrease in MC3T3-E1 cell index at 190 hours. None of the TADs had significant adverse effects on human gingival fibroblasts (Malkoc et al., 2012). Velasco-Ortega et al found that Ti-6Al-4V discs pretreated by a nitric acid passivation process were non-toxic to human or mouse fibroblasts. They noted that passivation will lead to a more dense stable oxide layer over the alloy surface and hence increase corrosion resistance (Velasco-Ortega et al., 2010). Interestingly another study done on MC3T3-E1 cells in contact with Titanium alloy discs (Ti-6Al-4V) reported a transient reduction in their cell viability at day 4. This decrease was restored by day 8 and completely eliminated after 15 days (360 hours) in culture. The authors attributed this transient alteration of cell viability to the chemical composition (Citeau et al., 2005). Okazaki et al. observed decreased growth ratio of MC3T3-E1 cells around Ti-6Al-4V alloys than in
the presence of pure titanium and suggested that it was because of toxic effects of released Vanadium ions (Okazaki et al., 1998).

To our knowledge, no other published study on mini-screws has studied potential cytotoxicity after submerging TADs in a dynamic cell culture medium for as long. Despite being an in vitro study, we have tried to mimic the in vivo conditions by simulating saliva flow and by submerging TADs for 720hrs (30 days) in an attempt to extract the highest possible level of toxic substances from the TADs, which is more stringent than the ISO standards in which 72 hours is the suggested longest period to test the acute effect of toxicity.

Like any experiment, there are areas which could be improved in the study design – namely greater sample size, longer incubation time in medium (3 months of incubation in MEM vs. 30 days), increased duration of cytotoxicity testing (48hrs, 72hrs, up to 190hrs).

To explore the possible relationship between the released metal ions from TADs and the cytotoxicity of the extracts of medium, quantitative evaluation of ion release at each time point should be performed. Due to the time limit and the focus of our study, we did not include a quantitative ion release study as part of this project, which obviously is a deficiency.

As we know, the mechanism of cytotoxicity can be cell necrosis (acute and usually by strong toxins) and apoptosis (a relatively longer time process and can be induced by mild toxins). In this study, we only tested the generic cytotoxicity of the TAD extract on the PDL cells without delineating its mechanism. This is beyond the scope of our study but can be further approached in future studies.
Considering the variables in methodology (discs vs. TADs, end point testing vs. real time cell analysis, incubation and testing duration), different cell origins, it is expected to see variable outcomes. Further standardized cytotoxicity testing using commercially available mini-screws in contact with different cell types (MC3T-E1, hPDLE, gingival fibroblasts) for longer durations may resolve some of the conflicting observations in the reported studies. The release of metal ions from orthodontic TADs might directly affect their biocompatibility. There are no exhaustive data correlating metal ion release from TADs, their biocompatibility and association with failure of orthodontic mini-implants or temporary anchorage devices.

Considering the rising clinical use of TADs in orthodontics, further investigations should be performed to facilitate better understanding of the biological effects of the TADs on oral tissues.
CONCLUSION

Under the conditions of this in vitro study, our results show that TADs from the four manufacturers generally exhibited similar insignificant cytotoxicity to human PDL fibroblasts, allowing us to accept the null hypothesis, that is, the TADs are not cytotoxic to hPDLF.


Cope JB. Semin Orthod 11:3-9 © 2005 TADs- paradigm shift


Lim S. Insertion torque of orthodontic mini-screws according to changes in shape, diameter and length. Angle Orthod 2008;78:234-40.


Proffit WR, Fields HW Jr. and Sarver DM. Contemporary Orthodontics, 5th Edition


Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng 2004;6:41–75.


Watanabe I, Wataha JC, Lockwood PE, Shimizu H, Cai Z, Okabe T. Cytotoxicity of commercial and novel binary titanium alloys with and without a surface-reaction


